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ABSTRACT
The human mitochondrial genome encodes 22
tRNAs interspersed among the two rRNAs and 11
mRNAs, often without spacers, suggesting that
tRNAs must be ef®ciently excised. Numerous
maternally transmitted diseases and syndromes
arise from mutations in mitochondrial tRNAs, likely
due to defect(s) in tRNA metabolism. We have sys-
tematically explored the effect of pathogenic muta-
tions on tRNAIle precursor 3¢ end maturation in vitro
by 3¢-tRNase. Strikingly, four pathogenic tRNAIle
mutations reduce 3¢-tRNase processing ef®ciency
(Vmax / KM) to ~10-fold below that of wild-type,
principally due to lower Vmax. The structural impact
of mutations was sought by secondary structure
probing and wild-type tRNAIle precursor was found
to fold into a canonical cloverleaf. Among the
mutant tRNAIle precursors with the greatest 3¢ end
processing de®ciencies, only G4309A displays a
secondary structure substantially different from
wild-type, with changes in the T domain proximal to
the substitution. Reduced ef®ciency of tRNAIle pre-
cursor 3¢ end processing, in one case associated
with structural perturbations, could thus contribute
to human mitochondrial diseases caused by mutant
tRNAs.
INTRODUCTION
The human mitochondrial genome encodes 22 tRNAs, one for
each of 18 amino acids, and two each for Leu and Ser with
different anticodons (1). Over 150 pathogenic mutations have
been found in the mitochondrial genome [see Mitomap (2) for
a compilation], most of them transitions in tRNA genes. Since
the tRNA genes combined constitute only approximately
one-tenth of the mitochondrial genome, defects in tRNA
function apparently contribute disproportionately to inherited
mitochondrial disease (reviewed in 3±5).
tRNAs are interspersed among the other functional
mitochondrial RNAs (two rRNAs and 11 mRNAs, which
encode 13 polypeptide subunits of the respiratory chain
complexes) on long precursor transcripts, often without
intergenic RNA. The 3¢ end CCA common to all mature
tRNAs is not mitochondrially encoded, and must be added to
the discriminator base by tRNA nucleotidyltransferase after
tRNA precursor 3¢ end processing. Punctuation of long
mitochondrial transcripts with tRNAs thus suggests a need
for precise, ef®cient endonucleolytic cleavage at both their 5¢
and 3¢ ends (6,7).
Punctuation of long, multi-functional human mitochondrial
transcripts by tRNAs suggests that end processing defects
arising from pathogenesis-linked tRNA mutations could
contribute to disease. Early results consistent with this
model include detection of a linked 16S rRNA-
tRNALeu(UUR)-ND1 transcript (RNA 19) in northern blots
from cells affected by pathogenesis-associated substitutions in
tRNALeu(UUR) (8,9). The idea was further investigated by
in vitro processing with culture cell extracts, using wild-type
and pathogenic tRNALeu(UUR) and tRNASer(UCN) transcripts
(10±12), and less ef®cient tRNA end processing with some of
the pathogenic substitutions was observed.
Human mitochondrial RNase P (10,13), 3¢-tRNase (10±12)
and tRNA nucleotidyltransferase activities (14,15) have been
characterized and, in the latter case, cloned and expressed.
3¢-tRNase may be important for maturation of both cyto-
plasmic and mitochondrial tRNAs (reviewed in 16). CC of
CCA at the 3¢ end of mature tRNAs is a 3¢-tRNase anti-
determinant (17), and tRNASer(UCN) with the T7445C {note
that two numbering schemes are used when referring to
mitochondrial tRNAs: based on position in the mitochondrial
genome [the Cambridge system (1)], in which tRNAIle runs
from 4263 to 4331 (Figs 2, 4 and 5, and Table 1), and the
system for numbering tRNAs from +1 to 76 (18,19) used in
Figs 1, 2, 3, 6, S1 and S2} substitution, which causes non-
syndromic deafness (20,21), changes the sequence of the
precursor from G/UCU to G/CCU following the discriminator
base, resembling a 3¢-tRNase anti-determinant. 3¢-tRNase
extracted from human culture cell mitoplasts was shown to
endonucleolytically cleave wild-type tRNASer(UCN) in vitro at
the expected processing site, and found to be unable to utilize
the T7445C mutant tRNASer(UCN) precursor as substrate (12).
This study laid the groundwork for a more general investiga-
tion of a possible relation between pathology-linked mutations
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in mitochondrial tRNAs and the ability of their precursors to
be 3¢ end processed.
Among human mitochondrial tRNAs, tRNALeu(UUR),
tRNALys and tRNAIle are hot spots, with 21, 10 and 10
known pathogenesis-associated mutations, respectively (2).
The effect of mutations in tRNAIle on aminoacylation by
mitochondrial isoleucyl-tRNA synthetase has already been
analyzed (22±25). Here, we further systematically consider
the effects of a number of pathogenesis-linked mutations in
tRNAIle on 3¢ end maturation by 3¢-tRNase and on tRNA
structure in solution.
Two pathological presentations are linked to mutations in
tRNAIle (Fig. 1): cardiomyopathies (mutations A4269G,
A4295G, A4300G, A4317G and C4320T) and ophthalmo-
plegia (mutations T4274C, T4285C, G4298A and G4309A).
For one further mutation, G4284A, a varied familial
presentation including both fatal cardiomyopathy and
ophthalmoparesis was observed (26).
The positions of the mutations within the tRNA 2D
cloverleaf structure (Fig. 1) do not display an obvious pattern
with respect to the different tRNA domains, nor is there an
evident relationship between the position of each mutation and
the disease it causes [the same can generally be said for
pathogenesis-associated mutations in human mitochondrial
tRNAs (27)]. All mutations are transitions; in stems, most of
them convert a Watson±Crick pair into a C´A or A´C mismatch
and one mutation (C4320T) converts a mismatch into a
Watson±Crick pair.
Here the 3¢ end processing of wild-type and variant tRNA-
Ile precursors was investigated using a fractionated mitoplast
extract, in which interactions could occur between substrate
and various factors which may be present. All the pathological
substitutions reduce 3¢-tRNase processing ef®ciency in vitro,
in several cases by ~10-fold. Thus, defective tRNA 3¢ end
processing could contribute to mitochondrial pathology.
Interestingly, the G4309A substitution, located close to the
A´C mismatch in the wild-type T stem, affects T domain
structure, which is generally important for tRNA recognition
and processing.
MATERIALS AND METHODS
Preparation of tRNA precursors
A set of plasmids with tRNAIle inserts (wild-type, A4269G,
T4274C, T4285C, A4295G, G4298A, A4300G, A4317G and
C4320T; Fig. 1) linked at +1 to a hammerhead ribozyme and
T7 promoter was a kind gift of Shana Kelley. In these inserts
[originally designed to run off at a BstNI site, producing full-
length CCA-terminated transcripts (+76) for aminoacylation
studies (23)], the CCA (nucleotides 74±76) was replaced by
PCR ampli®cation with the ®rst 20 nt of the 3¢ end sequence
¯anking the human mitochondrial tRNAIle precursor (5¢-
GGACUAUGAGAAUCGAACCC-3¢; Fig. 2A), including a
SmaI runoff site. Inserts were recloned into the small high
copy vector pHC624 and con®rmed by DNA sequencing. The
G4309A mutant tRNAIle precursor was constructed from
wild-type by ampli®cation using a 63 nt reverse primer
(from the subcloning site at the 5¢ end of the oligonucleotide
through sequence complementary to the 3¢ end trailer,
including the sequence from nucleotide 73 through the
substitution at nucleotide 51, and ending with the 3¢ end of
the oligonucleotide at nucleotide 41).
Unlabeled transcripts were prepared with T7 RNA poly-
merase as previously described (28), followed by phenol/
chloroform deproteinization and ethanol precipitation before
hammerhead self-cleavage of tRNAIle at the 5¢ side of +1.
tRNA precursors were puri®ed from the hammerhead on
denaturing 6% polyacrylamide gels, visualized by UV
shadowing, extracted from gel slices by diffusion for 30 min
at 37°C and recovered by ethanol precipitation, using oyster
glycogen as a carrier. Concentration of recovered tRNA was
determined by reading A260, using a conversion factor of
975 000 A260 M±1.
RNA labeling
tRNA precursors were labeled at their 5¢ ends with T4
polynucleotide kinase and [g-32P]ATP for 30 min at 37°C
using RNasin as a ribonuclease inhibitor, gel puri®ed,
visualized by autoradiography, and recovered from the gel
as described above. 3¢ End labeling was performed using T4
RNA ligase and [a-32P]Cp for 16 h at 4°C and precursors were
recovered as described above.
tRNA refolding
Both labeled and unlabeled tRNAs were re-folded by heating
in water for 5 min at 75°C and mixing with an equal volume of
Figure 1. Human mitochondrial tRNAIle secondary structure and patho-
logical substitutions. tRNAIle runs from nucleotides 4263 to 4331 using the
Cambridge mitochondrial genome numbering (1). Substitutions are identi-
®ed in the text by wild-type nucleotide, nucleotide number and mutation,
thus A4269G indicates that the wild-type A at position 4269 is replaced by
G in the mutant tRNA. Conventional tRNA nucleotide numbering (18,19) is
indicated in parentheses. Domain designations (bold) are: AcS, acceptor
stem; D, D domain; AC, anticodon domain; T, T domain. Nucleotide 4331
is the discriminator base, the last (unpaired) encoded nucleotide beyond the
acceptor stem which is retained after 3¢ end maturation, to which CCA is
added by tRNA nucleotidyltransferase. Mutations enclosed by rectangles
and ovals are those which cause cardiomyopathy and ophthalmoplegeia,
respectively. G4284A has a mixed presentation. References for these
mutations are listed on the web site www.gen.emory.edu/mitomap.html.
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heated buffer to a ®nal concentration of 25 mM Tris±HCl
pH 7.5, 250 mM KCl, 5 mM MgCl2 and 5% glycerol, and
allowed to cool to room temperature for 5 min.
3¢ End processing
The 3¢-tRNase processing extract was prepared from cultured
HeLa cell mitoplasts fractionated by DEAE±Sepharose
chromatography as previously described (12). Enrichment by
anion exchange removes most contaminating RNAs and some
contaminating proteins. Attempts to express human 3¢-tRNase
based on homology with Arabidopsis RNase Z (29) have so far
been unsuccessful (L.Levinger, unpublished results).
For Michaelis±Menten kinetics, re-folded unlabeled tRNA
precursor covering a concentration range centered on KM
(usually 0.4±10 3 10±8 M) was mixed with a ®xed amount of
5¢ end labeled precursor in a volume of 5 ml and placed at 4°C.
Processing reactions were initiated by adding 20 ml of a
reaction mix to make ®nal concentrations of 25 mM Tris±HCl
pH 7.5, 50 mM KCl, 1 mM MgCl2, 5% glycerol, 3 mM DTT,
40 U/ml RNasin with the 3¢-tRNase at a dilution of 1:60, and
placing the tubes at 37°C. Samples (5 ml) were taken after 6.6,
13.3 and 20 min of incubation and terminated by adding to
2.5 ml of formamide containing 0.53 TBE, 0.01% bromo-
phenol blue and 0.01% xylene cyanol at 4°C. Products were
separated by electrophoresis on 6% denaturing polyacryl-
amide gels until the xylene cyanol migrated 10 cm above the
bottom of the gels. Images were taken from dried gels using
a Fuji BAS 2000 phosphorimager and analyzed with
MacBas100 software.
Processing ef®ciency experiments were performed using
matched input radiolabeled substrates without added un-
labeled tRNA precursors. [S] is known to be much less than
KM under these conditions because the tRNA is labeled to high
speci®c activity and no unlabeled tRNA is added. The increase
in percentage of product per minute of reaction is thus a direct
measure of reaction ef®ciency (Vmax / KM). Michaelis±Menten
kinetics provide a more reliable estimate of reaction ef®-
ciency, however, since it is based on the independent
determination of KM and Vmax. Enzyme concentration is also
expected to be much less than [S], as required by the steady-
state assumption of Michaelis±Menten kinetics. This is
dif®cult to substantiate using mitoplast extract, but it is
generally thought that the concentration of mitochondrial
housekeeping enzymes such as those involved in tRNA
metabolism is limiting [see, for example, the arguments of
Puranam and Attardi (30) concerning the intramitochondrial
concentration of RNase P].
Structure probing
For alkaline ladders, the end-labeled tRNA was incubated at
90°C for 10 min in 50 mM NaHCO3, pH 9. For semi-
denaturing ribonuclease (RNase) T1 reactions, the labeled
tRNA was incubated at 55°C for 10 min in 12.5 mM Na
citrate, pH 4.5, 3.5 M urea, 0.5 mM EDTA. Unlabeled
Escherichia coli tRNA was used as a carrier at a ®nal
concentration of 1 mg/10 ml reaction. To achieve native
conditions, tRNAs were refolded as described above for
processing, and incubated in the processing buffer (but
without RNasin) for 5 min at 37°C with the structure probing
nucleases. Final concentrations were 1 and 2.5 3 10±3 U/ml
(RNase T1), 0.55 and 1.37 U/ml (nuclease S1) or 1 and 2.5 3
10±6 U/ml (RNase V1). Reactions were terminated by placing
samples at ±20°C. For electrophoresis on 30 3 40 cm, 6, 8 or
10% denaturing polyacrylamide gels, 5 ml of formamide-
marker dye mix was added and 7.5 ml samples were loaded
directly, without heating. Gels were electrophoresed until the
bromophenol blue migrated to 10 cm above the bottom.
Imaging and analysis were performed as for processing gels.
RESULTS
Human mitochondrial tRNAIle precursor 3¢ end
processing
Endonucleolytic removal of the 3¢ end trailer is central to the
maturation of human mitochondrial tRNA precursors. We
designed a tRNAIle precursor with a mature 5¢ end [the
presence of a 5¢ end leader can interfere with 3¢ end processing
(12,31,32)] and a 20 nt 3¢ end trailer (Fig. 2A; arrow indicates
the expected 3¢-tRNase cleavage site directly following the
discriminator base). The 5¢ end labeled precursor can be
ef®ciently processed by 3¢-tRNase extracted from human
culture cell mitochondria (Fig. 2B). Three bands of expected
product tRNA size are reproducibly obtained in similar
proportions, the most intense arising from the predicted
cleavage after the discriminator base (relative intensities of
nucleotide 73 > 74 >> 72). Product heterogeneity is not due to
3¢ end heterogeneity of T7 transcripts, since the precursor was
labeled at its 5¢ end. Such heterogeneity of 3¢-tRNase products
(Fig. 2B) has been observed with other combinations of
processing enzymes and substrates (12,32), including the
cloned and expressed Arabidopsis thaliana and
Methanococcus janeschii 3¢-tRNase (29). Quantitation of
processing kinetics was performed by combining the
intensities in the product region.
Figure 2. 3¢ End processing of wild-type tRNAIle precursor. (A) Wild-type
tRNAIle precursor with a 20 nt 3¢ end trailer used in these processing
studies. The arrow following the discriminator base indicates the major 3¢-
tRNase processing site (after the discriminator base, nucleotide 73). (B) 3¢
End processing. Lane M, labeled DNA marker. Lane 1, typical processing
reaction using 5¢ end labeled precursor. Designations on the right
correspond to the tRNA precursor (Pre) and product (tRNA).
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Selected pathological substitutions reduce the ability of
tRNAIle precursors to be processed by 3¢-tRNase
Ten mutations in human mitochondrial tRNAIle have been
shown to cause disease (Fig. 1). All the pathogenic tRNAIle
mutants tested reduced 3¢-tRNase processing ef®ciency;
Figure 3 illustrates the processing effects of the A4269G,
G4309A and A4317G substitutions. A4269G causes the
greatest decrease in processing ef®ciency (~12-fold less than
wild-type), and four of the eight mutants tested reduced
processing ef®ciency to ~10-fold below wild-type (see
below). In this experiment, almost 40% of the wild-type
precursor was converted to product in 15 min of reaction
(Fig. 3A, lane 4), close to the upper limit for 3¢-tRNase
processing of wild-type substrate produced by in vitro tran-
scription. Some mutant substrates display a lower end point
for processing than wild-type, as well as a reduced processing
ef®ciency.
Reduced 3¢-tRNase processing ef®ciency of mutation-
carrying tRNAIles is principally due to lower Vmax
Of the 10 tRNAIle mutations known to cause disease (Fig. 1),
we performed Michaelis±Menten kinetics on eight (Fig. 4 and
Table 1). G4298A was not included in the kinetic analysis
because it is located close to A4300G in the anticodon stem
(which was included) and its relative processing ef®ciency
was only slightly reduced (data not shown). A4317G was used
to illustrate wild-type and mutant processing kinetics (Fig. 4)
because it is located in the T loop, which is rich in processing
determinants (see Discussion), and displays a typically strong
reduction in Vmax while KM is practically unaffected. With
every mutant tested, Vmax for 3¢-tRNase was lower than with
wild-type. KMs for pathogenic tRNAIles were also consistently
less than for wild-type, but the decrease in Vmax (up to
~20-fold, in the case of A4269G) was consistently greater than
that for KM, so that processing ef®ciency (Vmax / KM) was
reduced for all the mutants, ~10-fold in the case of four mutant
tRNAIles (A4269G, A4295G, G4309A, A4317G; bold ®gures
in the right-most column of Table 1).
Figure 3. tRNAIle precursor 3¢ end processing of wild-type and selected
pathological mutants. 5¢ End labeled tRNAs were processed without added
unlabeled tRNA. (A) Wild-type, (B) A4269G, (C) G4309A, (D) A4317G.
Reactions were sampled after 0, 5, 10 and 15 min incubation at 37°C in
lanes 1±4 of each set. M is same as in Figure 2.
Figure 4. 3¢-tRNase processing kinetics of wild-type and A4317G precur-
sors. Processing reactions were performed using a series of unlabeled sub-
strate concentrations of 0.4, 1.0, 2.0, 4.0 and 10.0 3 10±8 M in (A) to (E),
respectively. Reactions were terminated after 6.6, 13.3 and 20 min of
incubation at 37°C in lanes 1±3 at each substrate concentration, respect-
ively. (A) Wild-type; (B) A4317G; (C) Eadie±Hofstee plot of V versus
V / [S], in which slope is ±KM and V intercept is Vmax. Because input
labeled tRNA is constant, the proportion of labeled product obtained per
minute of reaction, measured from these gels (A and B), is equivalent to
V / [S], which decreases with increasing [S], and V increases as expected
with increasing [S]. The reduced processing ef®ciency of the A4317G
mutant relative to wild-type tRNAIle (B) is due principally to reduced Vmax
(C). Similar results were obtained with the other mutants (data not shown;
Table 1), in which Vmax consistently decreased.
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Effect of mutations on tRNAIle precursor structure
We used secondary structure probing nucleases to investigate
precursor tRNAIle folding and to search for structural differ-
ences between the mutants and wild-type. Ribonuclease T1 is
speci®c for G residues, nuclease S1 for single-stranded
regions, and ribonuclease V1 for paired stems and otherwise
structured regions [note, however, that V1 cleavage as a literal
indicator of helicity can be misleading, missing some helices
and cutting to the sides of others (33); reliable comparisons
between mutant and wild-type V1 data can be made,
however]. Ribonuclease T1 used under semi-denaturing as
well as native conditions can reveal differences in exposure of
Gs which arise from tRNA folding. The four mutants which
gave the lowest processing ef®ciencies in Michaelis±Menten
experiments (A4269G, A4295G, G4309A, A4317G; see Fig. 1
for location) were 5¢ end labeled and probed with nucleases
alongside wild-type tRNAIle. No differences were observed
between wild-type precursor and three of the mutants
(A4269G, A4295G, A4317G; results not shown). Structural
differences observed between the wild-type and G4309A
patterns (Figs 5 and S1) were tightly clustered surrounding the
site of the G4309A substitution, as indicated by a vertical bar
to the right of Figure 5B.
All of the Gs from nucleotide 9 to the 3¢ end of the precursor
can be detected with roughly equal intensity in the semi-
denaturing T1 lanes (lanes 2 and 3 in both panels of Fig. 5).
The absence of G51 from the G4309A pattern (arrow at left of
Fig. 5B, lanes 2 and 3) con®rms the G4309A substitution. G34
in the anticodon loop is the most fully exposed T1 site in the
folded tRNA (native state, lanes 5 and 6, designated N T1),
consistent with the canonical tRNA fold. The S1 pattern
closely follows the T1 pattern (lanes 7 and 8), displaced up by
a single nucleotide (nucleases S1 and V1 leave a 3¢-OH, while
T1 leaves a 3¢-PO42±, so that corresponding T1 bands migrate
faster due to greater negative charge). Some secondary
structure was also observed in the 3¢ end trailer, based on
alternating S1 and V1 sensitivity downstream of nucleotide
73.
The distribution of V1 cleavages within tRNAIle precursors
is consistent with the cloverleaf structure of tRNA (bars and
numbers enclosed in ovals placed on the secondary structure
Table 1. Steady state 3¢-tRNase processing kinetics with wild-type and mutant tRNAIle precursors
Typea KM 3 10±8 Mb Vmax 3 10±10 M/min Vmax / KM 3
10±2 min±1
Loss in processing
ef®ciencyc
Wild-type 1.33 6 0.18 2.23 6 0.23 1.68 1.0
A4269G (7) 0.92 6 0.33 0.12 6 0.004 0.13 12.5
T4274C (12) 0.88 6 0.35 0.35 6 0.05 0.40 4.2
T4285C (27) 0.32 6 0.16 0.17 6 0.03 0.53 3.2
A4295G (37) 0.91 6 0.46 0.15 6 0.03 0.16 10.3
A4300G (42) 0.41 6 0.09 0.32 6 0.04 0.78 2.1
G4309A (51) 0.81 6 0.03 0.18 6 0.01 0.22 7.7
A4317G (59) 1.26 6 0.44 0.21 6 0.03 0.17 10.0
C4320T (62) 1.70 6 0.95 0.67 6 0.20 0.39 4.2
aNumbering of pathogenic mutants is both according to nucleotide position in the mitochondrial genome and
in accordance with conventional tRNA numbering (in parentheses).
bStandard error of the mean is indicated. Experiments on mutants were performed at least twice and the wild-
type experiment was performed nine times.
cRefers to the factor by which mutant precursor processing ef®ciency is reduced relative to wild-type.
Figure 5. Solution secondary structure probing of wild-type and G4309A
tRNAIle. tRNAs [wild-type and G4309A in (A) and (B), respectively] were
labeled at their 5¢ ends and cleaved with NaHCO3 to produce the alkali
ladder (lane 1, designated AL at bottom) and probed with ribonuclease T1
at 1 and 2.5 3 10±3 U/ml under semi-denaturing conditions (lanes 2 and 3,
respectively; SD T1). tRNAs re-folded under native conditions (see
Materials and Methods) were probed with T1 at 0, 1 and 2.5 3 10±3 U/ml
(lanes 4±6; N T1), with ribonuclease S1 at 0.55 and 1.37 U/ml (lanes 7±8)
and with ribonuclease V1 at 1 and 2.5 3 10±6 U/ml (lanes 9±10). Numbers
on the left designate T1 cleavages at Gs observed in the semi-denaturing T1
lanes. Designations on the right indicate regions and nucleotide numbers
corresponding to V1 cleavages, and numbers enclosed in ovals correspond
to regions that can be placed on the canonical tRNA structure (see Fig. 6).
The arrow on the left and the bar at the right of (B) indicate the position of
the G4309A substitution and a corresponding region of altered S1 and V1
sensitivity in this mutant (see Fig. 6).
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diagram in Fig. 6 correspond with those in Fig. 5). The bottom
of the T stem (nucleotides 49±53) displays low V1 sensitivity;
only nucleotide 49 is a strong V1 site in wild-type tRNAIle
precursor. The variable domain appears to be structured, as
suggested by V1 bands at nucleotides 44, 45 and 47, 48. V1
cleavage at nucleotide 55 and in the D loop could indicate
tertiary interactions (see Discussion).
Most structural changes in the G4309A precursor relative to
wild-type are just upstream from the mutation at nucleotide
51. Nucleotide 50 becomes highly susceptible to S1 (Fig. 5B,
lanes 7 and 8, scans of gels in Fig. S1) and nucleotide 49
becomes much less susceptible to V1 (Fig. 5B, lanes 9 and 10;
Fig. S1). In addition, V1 sensitivity of G4309A increases at T
loop nucleotide 55. Thus the structural effects of the G4309A
substitution are local, and only slightly propagated. The V1
sensitivity of the acceptor stem and top of the T stem (72±66
and 65±61, Fig. S1) in G4309A do not appear to be affected.
Comparison of native T1 (lanes 5±6) and S1 (lanes 7±8) with
semi-denaturing T1 (lanes 2±3) patterns in the G4309A
mutant (B) relative to wild-type (A) suggests that, in addition
to pronounced local effects noted above, the entire mutant
tRNA may be more exposed, consistent with a weakened
tertiary structure. Results with 3¢ end labeled tRNAIle
precursors are essentially the same (Fig. S2).
DISCUSSION
3¢-tRNase processing of a human mitochondrial tRNAIle
precursor
Mitochondrial tRNAs are embedded in long primary tran-
scripts, punctuating the two ribosomal RNAs and 11 mRNAs
(1). Production of mature, functional mitochondrial RNAs
requires endonucleolytic cleavage of the precursors at the 5¢
and/or 3¢ ends of the tRNAs (6,7). tRNAIle overlaps by 1 nt on
its 5¢ end with the 3¢ end of ND1 mRNA, which therefore
requires that 1 A be added after processing to complete the
ND1 translation termination codon. On the 3¢ side, tRNAIle is
¯anked by a 70 nt spacer followed by tRNAMet, making the
reductions in 3¢-tRNase processing ef®ciency that arise from
pathogenesis-associated mutations still more remarkable. The
same is true for tRNASer(UCN) (12), which is followed by a
2.5 kb spacer on the 3¢ side.
Human mitochondrial tRNAIle undergoes post-transcrip-
tional modi®cation at ®ve positions in vivo [to produce m1G9,
m22G26, Y27, Y28 and t6A37 (25)]. The in vitro 3¢-tRNase
reaction using unmodi®ed wild-type transcript is ef®cient
(Figs 2B and 3A), and excision of the tRNAs from precursor
transcripts is expected to occur early in tRNA metabolism; the
stage of tRNA maturation at which modi®cation occurs and in
most cases, the signi®cance of the modi®cations, are
unknown. Nonetheless, tRNA modi®cation could alter the
relative effects of pathogenesis-linked mutations on tRNA
precursor 3¢ end processing. Interestingly, three of the ®ve
tRNAIle modi®cations occur at positions that coincide
with pathogenesis-associated mutations (m22G26±G4284A;
Y27±T4285C; t6A37±A4295G).
Several pathogenic tRNAIle precursors substantially
reduce 3¢-tRNase processing ef®ciency, principally due
to lower Vmax
To date, 10 substitutions in tRNAIle have been linked to
mitochondrial diseases. Of these, we initially investigated the
effect of nine pathogenic tRNAIle substitutions on 3¢-tRNase
processing [we became aware of the G4284A mutation (26)
toward the end of this investigation]. All these substitutions
reduce the ef®ciency with which tRNAIle can be processed by
3¢-tRNase. The greatest reductions were observed with
mutations A4269G, A4295G, G4309A and A4317G.
On the basis of these reduced processing ef®ciencies, we
performed Michaelis±Menten kinetics on wild-type and eight
mutant tRNAIles (Fig. 4 and Table 1). A tRNAIle precursor
with the pathogenic A4317G mutation displays substantially
reduced Vmax compared with wild-type, with a lesser reduction
in KM. Most of the tRNAIle mutants display a similar pattern of
larger reductions in Vmax, re¯ecting the chemical step of
catalysis, accompanied by smaller reductions in KM (Table 1).
Reduced KM usually indicates tighter substrate binding, which
would improve catalytic ef®ciency (Vmax / KM), but the
consistently larger reductions in Vmax that arise from
pathogenic mutations cause catalytic ef®ciency to be reduced.
KM would be expected to increase in the event of structure
changes that affect substrate recognition and binding, but in
most cases, no such structure changes were observed (see
below). Processing ef®ciencies with A4317G and three
other mutant precursors are all reduced ~10-fold relative to
Figure 6. Secondary structure of the tRNAIle precursor. Nucleotides are
numbered according to Guan et al. (21) and Degoul et al. (22). Stems desig-
nated by lines and numbers enclosed in ovals correspond with the regions
of V1 sensitivity designated in Figure 5. The oblique arrow at nucleotide 51
indicates the G4309A substitution.
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wild-type. 3¢ End maturation defects could thus contribute to
pathogenicity of some of the mutations.
Wild-type tRNAIle precursor is in the cloverleaf
structure, and G4309A displays local structural
differences from wild-type
Mitochondrial tRNAs display many differences in sequence
and secondary structure from cytoplasmic tRNAs; tRNAIle is
one of the most highly conserved mammalian mitochondrial
tRNAs (reviewed in 19). Despite an unusually small D domain
and an A´C apposition in the T stem (Fig. 1), wild-type tRNAIle
displays a secondary structure consistent with canonical
tRNA. The bottom of the T stem (nucleotides 49±53) is
weakly cleaved by V1 except for nucleotide 49, consistent
with the suggestion that the 52´62 A´C apposition weakens the
T stem (23,24). G18,19 in the D loop and TYC in the T loop,
which are universally conserved in cytoplasmic tRNAs, are
replaced in human mitochondrial tRNAIle by AA and CUU,
respectively. Interestingly, V1 cleavages at D loop nucleotides
19, 20 and at T loop nucleotide 55 could re¯ect tertiary A-U
pairs which replace the canonical D/T loop base pairs.
Structure modeling predicts alternate foldings of mitochon-
drial tRNAIle (D.Friede and P.Schuster, personal communica-
tion), but the structure probing results (Fig. 6) are generally
more consistent with the canonical fold. The 3¢ end trailer is
evidently structured, but without obvious pairing partners. The
sequence of the 3¢ end trailer used in vitro (Fig. 2A),
characteristic of the tRNAIle precursor in vivo, is also present
on the mutants, thus the 3¢ end trailer is unlikely to interfere
differentially with 3¢ end processing.
Effect of a pathogenesis-linked substitution on secondary
structure
Mutant and wild-type secondary structures were compared in
search of a structural basis for reduced processing ef®ciency.
Apart from G4309A, the mutants do not display different
structures. G4309A is of particular interest because the
substitution is 1 nt upstream from a 52´62 A´C mismatch in
wild-type tRNAIle, and because it shows strongly reduced
3¢-tRNase processing ef®ciency. Differences between wild-
type and mutant G4309A precursors are observed with
enzymatic probes. S1 sensitivity of G4309A at nucleotide 50
increases, V1 sensitivity at nucleotides 49, 50 decreases just
upstream from the pathogenic substitution at nucleotide 51,
and nucleotide 55 increases in susceptibility to V1 nuclease in
the G4309A mutant. These local and slightly propagated
structure changes are located in a region which could be
important for 3¢-tRNase recognition and catalysis. End
processing reactions by RNase P, 3¢-tRNase and NTase
require an intact, coaxially stacked acceptor stem and T
domain (33). The location of the G4309A mutation in the T
stem and its structural, functional and physiological effects
are consistent with the idea that the structural changes
could interfere with its ability to be cleaved by 3¢-tRNase,
contributing to pathology.
Mutations A4269G and A4317G are also in the acceptor
stem and T domain of the tRNA. While these mutations do not
lead to detectable changes in secondary structure, the wild-
type nucleotides at these positions could be directly recog-
nized by 3¢-tRNase. For mutant A4295G, the strong reduction
in 3¢-tRNase processing ef®ciency is less interpretable, since a
mutation in the anticodon loop would not be expected to
interfere with 3¢ end processing.
An overview of tRNA maturation and aminoacylation in
the context of mitochondrial disease
Pathogenesis-linked mutations in mitochondrial tRNAs cause
a wide variety of diseases, syndromes and symptoms. The
speci®c position of a mutation in a particular tRNA does not
correlate in a simple, obvious way with the disease, but
interestingly, four pathogenic mutations in tRNASer(UCN) cause
sensorimotor deafness [see Mitomap (2) and Toompuu et al.
Table 2. Effects of mutations in tRNAIle associated with diseases on structure, precursor 3¢-tRNase
processing and aminoacylation
Location in
mitochondrial
genome
Location in
tRNA (nucleotide
position)
Diseasea Structural effect Loss in 3¢-tRNase
processing ef®ciencyb
Loss in
aminoacylation
ef®ciency
A4269G Acceptor stem (7) CM Stability decreasedc 12.5 1.3d
T4274C D-stem (12) OP ± 4.2 25d
G4284A Connector (26) Mixed ± ± ±
T4285C Anticodon stem (27) OP ± 3.2 50d
A4295G Anticodon loop (37) CM No changeb 10.3 0.77e
G4298A Anticodon stem (40) OP ± ±f >1000d
A4300G Anticodon stem (42) CM ± 2.1 5e
G4309A T-stem (51) OP Local changeb 7.7 ±
A4317G T-loop (59) CM No changeb 10.0 3.75d
C4320T T-stem (62) CM ± 4.2 0.6d
aCM, cardiomyopathy; OP, ophtalmoplegia; Mixed, both cardiomyopathy and ophtalmoplegia.
bThis work.
cYasukawa et al. (25); (±) not determined.
dKelley et al. (23,24).
eS. Kelley, personal communication.
fNot determined, but cleavage ef®ciency comparable to mutant A4300G.
Bold text is used to indicate those mutants which display the strongest reduction in either 3¢-tRNase or
aminoacylation ef®ciency, but not both (as discussed in text).
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(34)], and three mutations in tRNAIle that cause ophthalmo-
plegia (T4274C, T4285C and G4298A) also severely reduce
their ability to be aminoacylated (23).
Aminoacylation is the most-studied aspect of tRNAIle
metabolism for which the effects of pathogenesis-linked
mutations have been investigated (22±25). Results are
summarized in Table 2, along with the present ®ndings on 3¢
end maturation. Mutations which most strongly reduce 3¢ end
processing ef®ciency (A4269G, A4295G, A4317G; bold in
Table 2, column 5) have little or no effect on aminoacylation,
and those which affect processing the least (T4274C, T4285C,
G4298A; bold in Table 2, column 6) display reduced capacity
for aminoacylation, suggesting a reciprocal relationship.
Interference of a mutation mainly with processing could
reduce the level of mature but fully aminoacylable tRNA,
while interference of a mutation with aminoacylation could
lead to a normal steady state level of tRNA, but a decreased
level of aminacyl-tRNA.
A defect in any aspect of tRNA metabolism could lead to a
decrease in the steady-state level of functional tRNA. If
severe, multiple molecular defects arise from the same
mutation, the total decrease in steady-state level of functional
tRNA might be lethal. On the other hand, two mutations
(A4300G, C4320T) barely affect either 3¢ end processing or
aminoacylation; in these instances, the molecular defect could
lie elsewhere.
Kelley et al. (23,24) suggested that the 52´62 A´C mismatch
in wild-type tRNAIle is destabilizing and that mutations
elsewhere throughout the tRNA compound its effect. Of the
mutant tRNAIle structures we investigated, only G4309A
(51A; see Figs 1 and 6) clearly affects secondary structure,
reduces the ability of the precursor to be 3¢ end processed, and
causes disease. The G4309A effect on secondary structure is
local, affecting the two nucleotides upstream from the
mutation in mid-T stem, and nucleotide 55 in the T loop.
Yasukawa et al. (25) showed A4269G to be unstable relative
to wild-type tRNAIle by using thermal melting and suscepti-
bility to nucleases present in mitochondrial extract (Table 2),
but we did not detect a difference in secondary structure
between this mutant and wild-type. Subtle problems with
structure, folding and stability of pathogenic tRNAs might
lead to their reduced ability to be processed and contribute,
along with other de®ciencies, to mitochondrial disease.
Detection of the postulated mild or tertiary structural defects
which arise from pathogenesis-linked mutations would require
more sensitive structure probing methods.
The generally reduced ability of pathogenesis-linked mutant
tRNAIle precurors to be processed at their 3¢ ends observed
here (~10-fold, in the case of four of the mutants investigated)
is consistent with the suggestion that inef®cient end processing
of mutant tRNAs could contribute to pathology.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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